ARGEN-X

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

#SimilarOrganizations #People #Financial #Website #More

ARGEN-X

Social Links:

Linkedin

Twitter

Industry:

Biotechnology Clinical Trials Therapeutics

Founded:

2008-01-01

Address:

Rotterdam, Zuid-Holland, The Netherlands

Country:

The Netherlands

Website Url:

http://www.argenx.com

Total Employee:

501+

Status:

Active

Contact:

+320477772944

Email Addresses:

[email protected]

Total Funding:

1.95 B USD

Technology used in webpage:

IPhone / Mobile Compatible SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS ASP.NET IIS Sectigo SSL Sectigo Domain SSL

Similar Organizations

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

cocrystal-pharma-logo

Cocrystal Pharma

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics.

hookipa-pharma-logo

Hookipa Pharma

Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.

immunovia-logo

Immunovia

Immunovia is the center for translational cancer research in Lund, Sweden.

x4-pharmaceuticals-logo

X4 Pharmaceuticals

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.

Current Employees Featured

christophe-blanchetot_image

Christophe Blanchetot
Christophe Blanchetot Director Discovery @ arGEN-X
Director Discovery
2016-01-01

keith-woods_image

Keith Woods
Keith Woods Chief Operating Officer @ arGEN-X
Chief Operating Officer
2018-01-01

hans-de-haard_image

Hans De Haard
Hans De Haard CSO @ arGEN-X
CSO
2008-01-01

christophe-blanchetot_image

Christophe Blanchetot
Christophe Blanchetot Research Fellow @ arGEN-X
Research Fellow
2011-03-01

eric-castaldi_image

Eric Castaldi
Eric Castaldi CFO @ arGEN-X
CFO

Founder

tim-van-hauwermeiren_image

Tim Van Hauwermeiren

Stock Details

Company's stock symbol is NASDAQ:ARGX

Investors List

burrage-capital_image

Burrage Capital

Burrage Capital investment in Post-IPO Equity - arGEN-X

mpm-capital_image

MPM Capital

MPM Capital investment in Post-IPO Equity - arGEN-X

dafna-capital-management_image

Dafna Capital Management

Dafna Capital Management investment in Post-IPO Equity - arGEN-X

aquila-capital_image

Aquila Capital

Aquila Capital investment in Post-IPO Equity - arGEN-X

erasmus-mc-biomedical-fund_image

Erasmus MC Biomedical Fund

Erasmus MC Biomedical Fund investment in Series B - arGEN-X

pmv-eu_image

PMV

PMV investment in Series B - arGEN-X

omnes-capital_image

Omnes Capital

Omnes Capital investment in Series B - arGEN-X

seventure-partners_image

Seventure Partners

Seventure Partners investment in Series B - arGEN-X

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series B - arGEN-X

forbion-capital-partners_image

Forbion Capital Partners

Forbion Capital Partners investment in Series B - arGEN-X

Investments List

Date	Company	Article	Money raised
2019-02-06	Halozyme Therapeutics	arGEN-X investment in Post-IPO Equity - Halozyme Therapeutics	30 M USD

Official Site Inspections

http://www.argenx.com Semrush global rank: 467.41 K Semrush visits lastest month: 110.13 K

Host Informations
Whois Informations

Loading ...

More informations about "arGEN-X" on Search Engine